Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Matthew J. Rees, Hang Quach, Anna Kalff et al.|Blood|2025Cited by 3